| __timestamp | BioMarin Pharmaceutical Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 152500000 |
| Thursday, January 1, 2015 | 634806000 | 187800000 |
| Friday, January 1, 2016 | 661905000 | 184000000 |
| Sunday, January 1, 2017 | 610753000 | 167700000 |
| Monday, January 1, 2018 | 696328000 | 218600000 |
| Tuesday, January 1, 2019 | 715007000 | 187400000 |
| Wednesday, January 1, 2020 | 628116000 | 177700000 |
| Friday, January 1, 2021 | 628793000 | 122000000 |
| Saturday, January 1, 2022 | 649606000 | 123100000 |
| Sunday, January 1, 2023 | 746773000 | 122500000 |
| Monday, January 1, 2024 | 747184000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, research and development (R&D) are the lifeblood of innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Perrigo Company plc have demonstrated contrasting approaches to R&D investment. BioMarin, renowned for its focus on rare genetic diseases, has consistently increased its R&D budget, peaking at a 62% rise from 2014 to 2023. This commitment underscores BioMarin's dedication to pioneering treatments. In contrast, Perrigo, a leader in over-the-counter health products, has seen a 20% decline in R&D spending over the same period. This shift reflects Perrigo's strategic pivot towards optimizing existing product lines rather than expanding its research frontier. As the pharmaceutical industry faces mounting pressure to innovate, these trends highlight the diverse strategies companies employ to balance growth and sustainability.
Johnson & Johnson or Perrigo Company plc: Who Invests More in Innovation?
Gilead Sciences, Inc. vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Strategic Focus on R&D Spending
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and Perrigo Company plc
Analyzing R&D Budgets: Perrigo Company plc vs Protagonist Therapeutics, Inc.
Analyzing R&D Budgets: Perrigo Company plc vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Perrigo Company plc vs Dynavax Technologies Corporation